FeesSafety
Pluang+

FDA approval expected for Grail's Galleri cancer test in early 2027, key for insurer coverage and pricing.

Market News
22 Nov 2026, 08:07 WIB
The Motley Fool
View Source
Neutral
FDA approval expected for Grail's Galleri cancer test in early 2027, key for insurer coverage and pricing.

Grail expects FDA approval for its multi-cancer early detection test, Galleri, in early 2027, which could lead to Medicare and commercial insurer coverage. Despite mixed trial results, the test showed promise in detecting 12 deadly cancers, supporting FDA approval hopes. The key challenge remains how insurers will value the test, with pricing expected around $500-$600. Following FDA approval, Medicare will likely begin coverage analysis, influencing broader adoption and commercial viability.

Grail stock's 2026 outlook is framed here with a snapshot of the health sector on Pluang as of Nov 22, 2026 11:01 WIB: out of 150 priced US health stocks, 31 rose and 117 fell. Notable movers include FLNA (Cassava Sciences Inc) at USD 0.64 with a 14.52% gain and a Pluang order activity of 75% Sell / 25% Buy, NUWE (Nuwellis Inc) down 10.50% at USD 3.41, and CGC (Canopy Growth Corp) down 9.97% at USD 0.43. Typical hold times range from 35 to 40 days.

More News

Growth ETF down 18% since October; dividend ETF up 3%, showing benefits of combining both funds.

Growth ETF down 18% since October; dividend ETF up 3%, showing benefits of combining both funds.

Since early October, the Vanguard Morningstar Growth ETF has dropped about 18% from its record high, while the Schwab U.S. Dividend Equity ETF has risen roughly 3%. The growth ETF focuses on fast-growing tech and consumer stocks with high earnings gr...

Market News
Bullish
45 minutes ago
Yelp shifts focus to AI and data licensing as ad revenue dips, targeting $250M non-ad revenue by 2028

Yelp shifts focus to AI and data licensing as ad revenue dips, targeting $250M non-ad revenue by 2028

Yelp reported a 1% decline in Q3 2026 net revenue to $371 million due to weak local advertising demand. To counter this, the company is expanding AI-powered services like Yelp Host, which now handles 2.5 million calls annually, and aims to grow non-a...

Company Fundamentals
Neutral
59 minutes ago
Workiva's Q3 revenue rises 17% to $263M, driven by AI governance and new customer growth.

Workiva's Q3 revenue rises 17% to $263M, driven by AI governance and new customer growth.

Workiva reported a 17% year-over-year revenue increase to $263 million in Q3 2026, fueled by strong subscription sales and growth in large contracts. The company emphasizes AI-driven compliance with traceable audit trails, meeting rising regulatory d...

Company Fundamentals
Bullish
1 hour ago
SharonAI's annualized revenue to jump 8x to $400M in Jan 2027 as data centers go live.

SharonAI's annualized revenue to jump 8x to $400M in Jan 2027 as data centers go live.

SharonAI announced its annualized run rate revenue will increase from $50 million in September 2026 to between $400 million and $450 million by January 2027, driven by 30 megawatts of new data center power capacity coming online. The company finances...

Company Fundamentals
Bullish
2 hours ago
Chipotle outpaces CAVA in revenue but CAVA's rapid growth narrows the gap with 500 stores expanding fast.

Chipotle outpaces CAVA in revenue but CAVA's rapid growth narrows the gap with 500 stores expanding fast.

Chipotle Mexican Grill has consistently reported higher quarterly revenue than CAVA Group over the past eight quarters, with Chipotle's sales reaching over nine times CAVA's volume. However, CAVA is rapidly expanding its store count, reaching 500 loc...

Market News
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App